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Active Ulcerative Colitis Trials (ACT-1 and ACT-2) to assess
relationships between serum concentrations of inﬂiximab and
outcomes of adults with moderate-to-severe ulcerative colitis.
METHODS: We compared serum concentrations of inﬂiximab
with outcomes of 728 patients with moderately-to-severely
active ulcerative colitis who participated in ACT-1 or ACT-2;
efﬁcacy data were collected at weeks 8, 30, and 54 (for
ACT-1 only). Relationships between serum concentration of
inﬂiximab and efﬁcacy outcomes were assessed using trend,
logistic regression, and receiver operating characteristic curve
analyses. We also evaluated factors that affected the relation-
ship between exposure and response. RESULTS: Median serum
concentrations of inﬂiximab at weeks 8, 30, and/or 54 were
signiﬁcantly higher in patients with clinical response, mucosal
healing, and/or clinical remission than in patients who did not
meet these response criteria. There were statistically signiﬁcant
relationships between quartile of inﬂiximab serum concentra-
tion and efﬁcacy at these time points (P < .01). Inﬂiximab
therapy was effective for a smaller proportion of patients in the
lowest quartile, and these patients had lower serum levels of
albumin and a higher incidence of antibodies to inﬂiximab than
patients in other quartiles. Although the relationship between
exposure to inﬂiximab and response varied among patients,
approximate serum concentrations of 41 mg/mL inﬂiximab at
week 8 of induction therapy and 3.7 mg/mL at steady-state
during maintenance therapy produced optimal outcomes in
patients. CONCLUSIONS: Serum concentrations of inﬂiximab
are associated with efﬁcacy in patients with moderate-to-
severe ulcerative colitis; however, complex factors determine
the relationship between exposure to this drug and response. A
prospective evaluation of the value of measuring serum con-
centrations of inﬂiximab should be performed before these data
can be included in patient management strategies. Clinicaltrials.
gov numbers: NCT00036439 and NCT00096655.Abbreviations used in this paper: ACT-1, Active Ulcerative Colitis Trial 1;
ACT-2, Active Ulcerative Colitis Trial 2; ATI, antibodies to inﬂiximab; AUC,
area under the curve; CI, conﬁdence interval; CPW2/6/14/30/54, pre-
infusion concentration at weeks 2/6/14/30/54; CW8, concentration at
week 8; IBD, inﬂammatory bowel disease; NPV, negative predictive value;
PK, pharmacokinetic; PPV, positive predictive value; ROC, receiver
operator characteristic; TNF, tumor necrosis factor; UC, ulcerative colitis.Keywords: Anti–Tumor Necrosis Factor; Monoclonal Antibody;
Pharmacokinetics; Inﬂammatory Bowel Disease.
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Iclonal antibody that neutralizes the biologic activity of
tumor necrosis factor (TNF)-a. Inﬂiximab is approved for the
treatment of patients with moderate-to-severe ulcerativecolitis (UC) based on the results of the Active Ulcerative
Colitis Trials 1 and 2 (ACT-1 and ACT-2), which evaluated
728 patients with moderate-to-severe disease. In these
studies, patients treated with inﬂiximab at weeks 0, 2, and 6
and every 8 weeks thereafter were more likely to show
clinical response, clinical remission, and mucosal healing at
weeks 8, 30, and 54 than patients assigned to placebo.1,2
Previous pharmacokinetic (PK) evaluations of inﬂiximab
use in patients with UC have shown a linear relationship
between dose and serum inﬂiximab concentration,3 and that
the systemic disposition of inﬂiximab is inﬂuenced by body
weight, serum albumin level, and the formation of anti-
bodies to inﬂiximab (ATI).4 In addition, serum inﬂiximab
concentrations have been found to inﬂuence the response to
treatment in Crohn’s disease,5,6 rheumatoid arthritis,7 and
psoriasis.8
Therapeutic drug monitoring potentially can improve
outcomes in patients receiving TNF antagonists, particularly
in those who have lost response to these agents owing to
inadequate serum drug concentrations.9 As such, knowledge
of the target serum inﬂiximab concentrations required for
efﬁcacy in both induction and maintenance may improve
clinical decision making in UC.
Several studies have reported a positive association be-
tween inﬂiximab concentration and efﬁcacy outcomes in
patients with inﬂammatory bowel disease (IBD);10–14 how-
ever, there are limited reports on speciﬁc concentration
thresholds for optimal efﬁcacy in UC. In 1 study that iden-
tiﬁed speciﬁc inﬂiximab cut-off levels, the analysis was
based on concentration data predominantly from patients
with Crohn’s disease and included relatively few patients
with UC (n ¼ 13).14 Given the differences in pathophysi-
ology and response to treatment between Crohn’s disease
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in the exposure-response relationship of anti-TNF therapies
when used to manage these conditions.9 Hence, evaluation
of the relationship between serum inﬂiximab concentrations
and efﬁcacy based on data from well-controlled clinical
trials in UC patients may help to identify target serum
inﬂiximab concentrations that can be used to guide thera-
peutic decisions in an effort to optimize clinical outcomes in
these patients.
We performed post hoc analyses of data from the ACT-1
and ACT-2 trials to assess the relationship between serum
inﬂiximab concentrations and clinical outcomes and to
identify clinically relevant drug concentrations to target in
pursuit of better clinical outcomes.
Patients and Methods
Patients
ACT-1 and ACT-2 (Clinicaltrials.gov numbers: NCT00036439
and NCT00096655) were randomized, double-blind, placebo-
controlled, phase 3 clinical trials conducted globally. A total of
728 patients were randomized at 62 sites in ACT-1 (N ¼ 364)
and at 55 sites in ACT-2 (N ¼ 364). The institutional review
board or ethics committee at each site approved the protocols,
and all patients provided informed consent. A patient disposi-
tion ﬂow chart for the present analyses is shown in Figure 1.
Study Design
The ACT-1 and ACT-2 trials were conducted in compliance
with the principles of the Declaration of Helsinki and GoodFigure 1. Patient disposi-
tion through the PK ana-
lytic time points of interest
in the ACT-1 and ACT-2
trials.Clinical Practices. The design and conduct of these trials
have been reported previously.2 Brieﬂy, all patients had an
established diagnosis of moderately-to-severely active UC, with
a Mayo score15 of 6 to 12 points (range, 0–12; with higher
scores indicating more severe disease activity), despite con-
current treatment with corticosteroids, azathioprine, or
6-mercaptopurine (ACT-1 and ACT-2), or mesalamine (ACT-2
only). Patients diagnosed with indeterminate colitis, Crohn’s
disease, or clinical ﬁndings suggestive of Crohn’s disease (ie,
ﬁstula or granuloma on biopsy) were excluded. As previously
described, concurrent therapy was not required at enrollment
for patients who could not tolerate or who previously failed to
respond to these medications.2 Doses of concomitant medica-
tions remained constant except for corticosteroids, which were
tapered to discontinuation after induction and during mainte-
nance therapy (ie, from week 8 forward).2
Patients were randomized equally to receive intravenous
infusions of inﬂiximab 5 mg/kg, inﬂiximab 10 mg/kg, or
placebo at weeks 0, 2, and 6 and then every 8 weeks through
week 22 (ACT-2) or week 46 (ACT-1) (Supplementary
Figure 1). Although inﬂiximab is indicated for the treatment
of UC only as a 5-mg/kg dose regimen, for the purpose of these
analyses, data from patients who received the 10-mg/kg dose
regimen in the ACT-1 and ACT-2 trials were included for a more
robust evaluation and interpretation of the concentration-
response relationship.
Study Evaluations and Analyses
Clinical outcomes were assessed using the Mayo score at
week 8 (ACT-1 and ACT-2), at week 30 (ACT-1 and ACT-2), and
at week 54 (ACT-1 only). Clinical response, deﬁned as a
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points and at least 30%, and with an accompanying decrease in
the rectal bleeding subscore of at least 1 point or an absolute
rectal bleeding subscore of 0 or 1, was the primary end point
for both the ACT-1 and ACT-2 trials. Clinical remission was
deﬁned as a total Mayo score of 2 points or lower, with no
individual subscore exceeding 1 point. Mucosal healing was
deﬁned by an endoscopy subscore of 0 or 1.
For PK evaluations, patients were followed up through
week 54 in ACT-1 or through week 42 in ACT-2. In ACT-1,
blood samples for determining serum inﬂiximab concentra-
tions were drawn just before and 1 hour after the infusions at
weeks 0, 2, 6, 14, and 46, and just before the infusions at weeks
30 and 38. Additional blood samples for determination of
serum inﬂiximab concentrations were drawn at the week-8 and
week-54 nondosing visits (Supplementary Figure 1). In ACT-2,
blood samples were drawn just before and 1 hour after the
infusions at weeks 0 and 2, and just before the infusions at
weeks 6 and 14. Additional blood samples for serum inﬂiximab
concentration analysis were drawn at the week-8, week-30, and
week-42 nondosing visits (Supplementary Figure 1). Serum
inﬂiximab concentrations were determined using a validated
enzyme-linked immunosorbent assay,16 with a lower limit of
quantiﬁcation of 0.1 mg/mL. Of the 484 patients randomized to
inﬂiximab (5 or 10 mg/kg) in the ACT-1 and ACT-2 trials, 482
received at least 1 infusion and had appropriate serum inﬂix-
imab concentration data. ATI were determined using an
antigen-bridging enzyme immunoassay.16 Similar to other
enzyme immunoassays, this assay was susceptible to drug
interference and was not able to detect ATI accurately in the
presence of a measurable inﬂiximab concentration. For the
purpose of this analysis, patients were classiﬁed as positive if
ATI were detected in their serum samples at any visit, whereas
all other patients were regarded as nonpositive for ATI.
Statistical Analysis
The patient population for these analyses included only
those who received at least 1 infusion of inﬂiximab at a dose of
5 or 10 mg/kg. Only patients with available inﬂiximab con-
centration data at the time point of interest were analyzed;
missing serum inﬂiximab concentration data were not imputed.
Serum inﬂiximab concentrations and efﬁcacy outcomes at week
8 (time for induction efﬁcacy end points for both ACT-1 and
ACT-2), week 30 (time for maintenance end points for both
ACT-1 and ACT-2), and week 54 (additional time for mainte-
nance end points for only ACT-1) were the primary focus of
these analyses. The prognostic value of earlier inﬂiximab con-
centrations on subsequent efﬁcacy outcomes also was
evaluated.
Patient characteristics and serum inﬂiximab concentration
data were summarized using descriptive statistics. The corre-
lation between serum inﬂiximab concentrations at different
time points was assessed using the Pearson correlation coefﬁ-
cient. Serum inﬂiximab concentration data were compared
between patients with and without the speciﬁed efﬁcacy out-
comes using a 2-sided Wilcoxon–Mann–Whitney, 2-sample,
rank-sum test. Serum inﬂiximab concentrations also were
categorized into quartiles, and the trend of the proportion of
patients with clinical outcomes across the quartiles was eval-
uated using the 1-sided Cochrane–Armitage trend test. Com-
parison of the proportions of patients with a given efﬁcacyoutcome across serum inﬂiximab concentration quartiles or
across a given categoric variable was performed using the
Fisher exact test, and the Kruskal–Wallis test was used to
compare continuous variables across quartile groups. The
association between serum inﬂiximab concentration (log-
transformed) and clinical outcomes was evaluated further by
multivariable logistic regression modeling.
The effects of covariates (body weight, age, albumin,
C-reactive protein level, Mayo score, sex, ATI status, and the
use of immunosuppressive agents and corticosteroids) were
assessed by logistic regression analyses. A backward elimination
approach using a signiﬁcance level of .05 for a covariate as a
requirement for continued inclusion in the model was adopted.
Receiver operating characteristic (ROC) curve analysis was used
to identify inﬂiximab concentration thresholds associated with
efﬁcacy during induction and maintenance. Optimal thresholds
were chosen using the Youden17 index, which maximizes the
sum of the speciﬁcity and sensitivity of the ROC curve.
All authors had access to the study data and reviewed and
approved the ﬁnal manuscript.Results
Baseline Characteristics in Patients With PK Data
The baseline characteristics of patients who partici-
pated in ACT-1 and ACT-2 have been detailed.2 A summary
of characteristics for patients who were randomized to
inﬂiximab treatment in both studies is provided in
Supplementary Table 1.
Serum Inﬂiximab Concentrations by Clinical
Response Status
The distribution of serum inﬂiximab concentrations
observed at each visit through week 30 in patients receiving
inﬂiximab 5 or 10 mg/kg is shown in Supplementary
Figure 2. When assessed by clinical response status (using
total Mayo score) at week 8, serum inﬂiximab concentra-
tions over time were higher among patients with clinical
response than among patients without response, as illus-
trated for both dose regimens in Figure 2. For each dose
regimen, the median serum inﬂiximab concentration was
signiﬁcantly higher at week 8 in patients with clinical
response or mucosal healing during induction than those
not achieving these end points (Table 1). For example, the
median serum inﬂiximab concentration at week 8 in clinical
responders was 35.0 mg/mL compared with 25.8 mg/mL in
clinical nonresponders for the 5-mg/kg group at week 8.
Similar results were observed for clinical response and
mucosal healing during maintenance at week 30 and week
54 (Table 1). For example, in patients who received the
5-mg/kg regimen, the median trough serum inﬂiximab
concentration in clinical responders was several-fold that of
clinical nonresponders (eg, 3.9 vs 1.2 mg/mL at week 30 and
5.0 vs 0.7 mg/mL at week 54, respectively).
With respect to clinical remission among patients in
the 5-mg/kg group, the median serum inﬂiximab concen-
tration at week 8 was not signiﬁcantly higher in week-8
remitters than in nonremitters (35.1 vs 30.8 mg/mL;
P ¼ .097). By comparison, the difference in serum inﬂiximab
Figure 2. Serum inﬂiximab concentrations over time by clinical response status at week 8 in patients randomized to inﬂiximab
(A) 5 mg/kg or (B) 10 mg/kg in ACT-1 and ACT-2. The pharmacokinetic proﬁle shown is according to the sampling times in
ACT-1 and ACT-2.
December 2014 Inﬂiximab Concentration and Outcomes in UC 1299
CL
IN
IC
AL
ATconcentrations between remitters and nonremitters at week
8 was statistically signiﬁcant for the 10-mg/kg dose group
(P ¼ .0002) (Table 1). The median serum inﬂiximab con-
centration was signiﬁcantly higher in remitters than non-
remitters at week 30 (P < .0001) and week 54 (P < .005),
regardless of inﬂiximab dose (Table 1).
Although median serum inﬂiximab concentrations were
consistently higher in patients with positive efﬁcacy out-
comes than those who failed to achieve these outcomes,
there was some overlap of the distribution of serum inﬂix-
imab concentrations between these groups. The overlap,
however, was greater during induction at week 8, but less
prominent during maintenance at week 30 or week 54. It
also appears that there was more variability of serum
inﬂiximab concentrations in patients who failed to respond
during maintenance (Figure 3).Efﬁcacy Outcomes by Serum Inﬂiximab
Concentration Quartiles
When assessed by inﬂiximab concentration quartiles, the
proportions of patients with treatment success as deﬁned
by multiple outcome measures (ie, clinical response,
mucosal healing, and/or clinical remission) generally
increased with increasing inﬂiximab concentration for the
5-mg/kg dose regimen. In each case, a signiﬁcantly positive
association was observed for the relationship between
serum inﬂiximab concentration quartiles and clinical out-
comes (Supplementary Figure 3). Patients with serum
inﬂiximab concentrations in the lowest quartile consistently
were less likely to show clinical response, clinical remission,
or mucosal healing and had rates of success approaching
those observed in patients assigned to placebo.2 Notably,
this ﬁnding was still evident when the quartiles wereexamined for the 10-mg/kg dose regimen, as illustrated for
the end point of clinical response in Supplementary
Figure 4. In general, patients with inﬂiximab concentra-
tions in the lowest quartile were more likely to have a lower
serum albumin concentration and to be positive for ATI than
patients in the other inﬂiximab concentration quartiles
(Table 2).Logistic Regression and Identiﬁcation of Optimal
Inﬂiximab Concentration Thresholds for Efﬁcacy
Multivariable logistic regression analyses were per-
formed to identify covariates that may inﬂuence the
exposure-response relationship for inﬂiximab in UC patients
receiving 5 mg/kg or 10 mg/kg during induction and
maintenance treatment. The ﬁnal logistic regression model
for induction treatment through week 8 showed that higher
serum inﬂiximab concentration at week 8, higher body
weight, and female sex were associated independently with
clinical response at week 8. Similar analyses conducted
through week 30 of maintenance treatment showed that a
higher inﬂiximab concentration at week 30 and absence of
corticosteroid therapy at baseline were associated inde-
pendently with a greater probability of maintaining clinical
response at week 30 (Supplementary Table 2).
To identify optimal inﬂiximab concentration target
thresholds associated with clinical improvement in UC
patients, ROC curves were generated for efﬁcacy end points
during both induction and maintenance treatment periods.
The ROC curves for the end point of clinical response in
patients who received the 5-mg/kg or 10-mg/kg inﬂiximab
dose regimen are shown in Figure 4 for induction and
maintenance treatment. Although the magnitude of the area
under the ROC curves (AUC) was moderate for the induction
Table 1.Summary of Medians (Interquartile Ranges) of Serum Inﬂiximab Concentration by Efﬁcacy Outcome Status in ACT-1
and ACT-2
Week-8 efﬁcacy outcome after inﬂiximab induction treatment
5 mg/kg (n ¼ 230) 10 mg/kg (n ¼ 216) Combined 5 and 10 mg/kg (n ¼ 446)
Efﬁcacy
outcome
Summary
statistic Achieved Not achieved Achieved Not achieved Achieved Not achieved
Clinical
response
n (%) 160 (69.6) 70 (30.4) 153 (70.8) 63 (29.2) 313 (70.2) 133 (29.8)
SIC 35.0 (25.0–50.5) 25.8 (17.8–39.5) 82.6 (56.7–108.4) 52.4 (26.1–91.0) 51.6 (31.7–85.8) 33.5 (20.8–64.4)
P valuea .0012 <.0001 <.0001
Mucosal
healing
n (%) 146 (63.5) 84 (36.5) 142 (65.7) 74 (34.3) 288 (64.6) 158 (35.4)
SIC 36.1 (25.8–51.6) 26.0 (17.9–38.8) 83.6 (57.2–109.8) 52.5 (31.6–90.5) 53.1 (33.2–88.8) 33.5 (21.2–63.1)
P valuea <.0001 <.0001 <.0001
Clinical
remission
n (%) 87 (37.8) 143 (62.2) 71 (32.9) 145 (67.1) 158 (35.4) 288 (64.6)
SIC 35.1 (24.7–49.0) 30.8 (20.4–46.5) 89.6 (68.2–117.3) 68.3 (39.5–96.6) 49.0 (32.1–89.6) 42.3 (24.5–77.6)
P valuea .0971 .0002 .0156
Week-30 efﬁcacy outcome during maintenance treatment
5 mg/kg (n ¼ 190) 10 mg/kg (n ¼ 184) Combined 5 and 10 mg/kg (n ¼ 374)
Clinical
response
N (%) 119 (62.6) 71 (37.4) 130 (70.7) 54 (29.4) 249 (66.6) 125 (33.4)
SIC 3.9 (0.7–7.6) 1.2 (0.1–3.6) 10.9 (3.9–18.3) 2.2 (0.1–4.8) 6.2 (2.0–15.2) 1.2 (0.1–4.4)
P valuea .0006 <.0001 <.0001
Mucosal
healing
N (%) 117 (61.6) 73 (38.4) 124 (67.4) 60 (32.6) 241 (64.4) 133 (35.6)
SIC 4.1 (1.1–8.4) 1.0 (0.1–3.0) 11.5 (3.9–18.5) 2.3 (0.1–5.5) 6.5 (2.4–15.3) 1.2 (0.1–4.7)
P valuea <.0001 <.0001 <.0001
Clinical
remission
N (%) 72 (37.9) 118 (62.1) 85 (46.2) 99 (53.8) 157 (42.0) 217 (58.0)
SIC 5.0 (2.3–10.8) 1.2 (0.1–4.6) 13.3 (6.3–18.3) 3.7 (0.2–7.8) 8.0 (3.5–16.7) 2.0 (0.1–6.5)
P valuea <.0001 <.0001 <.0001
Week-54 efﬁcacy outcome during maintenance treatment (ACT-1 only)
5 mg/kg (n ¼ 78) 10 mg/kg (n ¼ 80) Combined 5 and 10 mg/kg (n ¼ 158)
Clinical
response
n (%) 53 (68.0) 25 (32.1) 52 (65.0) 28 (35.0) 105 (66.5) 53 (33.5)
SIC 5.0 (2.5–9.3) 0.7 (0.1–2.8) 10.5 (4.8–19.1) 0.4 (0.1–5.4) 6.1 (3.0–14.9) 0.7 (0.1–4.2)
P valuea .0008 <.0001 <.0001
Mucosal
healing
n (%) 54 (69.2) 24 (30.8) 55 (68.8) 25 (31.3) 109 (69.0) 49 (31.0)
SIC 5.1 (2.5–9.8) 1.1 (0.1–2.7) 10.5 (4.6–18.9) 0.1 (0.1–3.1) 6.5 (3.0–14.9) 0.7 (0.1–3.1)
P valuea .0003 .0001 <.0001
Clinical
remission
n (%) 42 (53.9) 36 (46.2) 41 (51.3) 39 (48.8) 83 (52.5) 75 (47.5)
SIC 5.0 (2.6–9.8) 1.9 (0.1–6.5) 10.9 (5.9–19.2) 2.2 (0.1–11.1) 6.8 (3.2–15.0) 2.1 (0.1–8.1)
P valuea .0047 .0004 <.0001
NOTE. Values are shown in mg/mL.
SIC, serum inﬂiximab concentration.
aP value was derived from 2-sided Wilcoxon–Mann–Whitney 2-sample rank-sum test comparing patients who achieved vs
those who did not achieve the efﬁcacy outcome.
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(ie, week-8 concentration (CW8) compared with clinical
response at week 8), it was signiﬁcantly greater than the
null value of 0.5 (P < .0001). Furthermore, the AUC under
the ROC curve for the preinfusion concentration at week 6
(CPW6) (0.62; 95% CI, 0.57–0.66) was not signiﬁcantly
different from that using CW8 (P ¼ .553). In contrast, the
preinfusion inﬂiximab concentration at week 2 (CPW2) was
a poor predictor of clinical response at week 8 (AUC, 0.51).
With respect to the maintenance ROC curve analysis, the
AUC was 0.71 (95% CI, 0.66–0.76) for the week-30preinfusion concentration (CPW30) vs clinical response at
the week-30 ROC curve and 0.75 (95% CI, 0.68–0.82) for the
week-54 preinfusion concentration (CPW54) vs clinical
response at the week-54 ROC curve. The AUC from the ROC
curve of the serum inﬂiximab preinfusion concentration at
week 14 (CPW14) (0.68; 95% CI, 0.63–0.72) was comparable
with that of the CPW30 for the clinical response at week 30
(P ¼ .087) but was not equivalent to that from the CPW54
ROC curve for the week-54 clinical response end point (P ¼
.041). In addition, the AUC from the CPW30 ROC curve was
comparable with that from the CPW54 ROC curve (P¼ .746).
Figure 3. Distribution of inﬂiximab concentrations by efﬁcacy outcome status at (A) induction week 8, (B) maintenance week
30, and (C) maintenance week 54 (ACT-1 only) among patients treated with inﬂiximab 5 or 10 mg/kg. Box plots show the
median (solid line within box), interquartile range (upper and lower box boundaries), and standard deviation (whiskers).
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depending on the time point of the PK sampling or the
efﬁcacy assessment (Table 3). For clinical response at week
8, the threshold inﬂiximab concentration of 41 mg/mL at
week 8 was associated with a sensitivity, speciﬁcity, and
positive predictive value (PPV) of 63%, 62%, and 80%,
respectively. Similarly, to maintain clinical response, an
inﬂiximab threshold concentration of 3.7 mg/mL at week 30
was associated with a sensitivity, speciﬁcity, and PPV of 65%,
71%, and 82%, respectively. The data at week 54 suggest a
range for serum inﬂiximab concentrations of similar sensi-
tivity, speciﬁcity, and PPV, although the data represent a
subset of patients assessed (ie, only those from ACT-1).Serum Inﬂiximab Concentration and Subsequent
Efﬁcacy Outcomes
Serum inﬂiximab concentrations at earlier time points
were compared between patients who maintained or who
did not maintain an efﬁcacy outcome. Serum concentrations
at week 8 and week 14 were examined for their impact on
week-30 outcomes (ACT-1 and ACT-2 combined), whereas
concentrations at week 30 were examined for their impact
on week-54 outcomes (ACT-1 only). The results of these
analyses show that patients who previously achieved an ef-
ﬁcacy outcome but who subsequently failed to maintain that
outcome showed lower serum inﬂiximab concentrations
Table 2.Summary of Patient Characteristics by Serum Inﬂiximab Concentration Quartiles at Induction Week 8 and
Maintenance Week 30 Among Patients Treated With Inﬂiximab 5 or 10 mg/kg in ACT-1 and ACT-2
Characteristica Q1 Q2 Q3 Q4 P valueb
Induction week 8, n 111 112 111 112
Continuous variables, median
Body weight, kg 72.3 78.6 74.5 79.1 .035
Age, y 42.0 41.0 38.0 39.0 .140
Serum albumin level, g/dL 3.9 4.1 4.1 4.2 <.0001
C-reactive protein level, mg/dL 0.8 0.9 0.8 0.5 .005
Mayo score 9.0 8.0 8.0 8.0 .003
Categoric variables, %
Male sex 65.8 62.5 55.0 57.1 .338
Positive antibodies-to-inﬂiximab status 14.4 10.7 2.7 1.8 .0002
Concomitant immunomodulator usec 45.1 42.9 47.8 47.3 .881
Corticosteroid use 62.2 57.1 52.3 53.6 .448
Maintenance week 30, n 93 94 93 94
Continuous variables, median
Body weight, kg 75.0 76.3 79.0 75.7 .426
Age, y 45.0 41.0 40.0 38.0 .104
Serum albumin level, g/dL 4.0 4.1 4.2 4.2 <.0001
C-reactive protein level, mg/dL 0.9 0.8 0.6 0.7 .142
Mayo score 9.0 8.0 8.0 8.0 .13
Categoric variables, %
Male sex 59.1 59.6 63.4 55.3 .736
Positive antibodies-to-inﬂiximab status 25.8 3.2 3.2 0.0 <.0001
Concomitant immunomodulator usec 29.0 54.3 59.1 44.7 .0002
Corticosteroid use 57.0 54.3 60.2 46.8 .297
Q, quartile.
aAll characteristics are at baseline with the exception of antibodies-to-inﬂiximab status.
bP value derived from the Fisher exact test for categoric variables and the Kruskal–Wallis test for continuous variables.
cAzathioprine, 6-mercaptopurine, or methotrexate.
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ATearlier in their therapy than did patients who maintained the
efﬁcacy outcome. This ﬁnding is illustrated for the remission
outcome in Supplementary Figure 5A–C. In general, the
lower the inﬂiximab concentration at a given time point, the
more likely the patients were to fail to maintain remission
(Supplementary Figure 5D–F). Similar ﬁndings were
observed when individual inﬂiximab doses were analyzed, as
illustrated in Supplementary Figure 6A–D.Discussion
In these post hoc analyses of the ACT-1 and ACT-2 data,
we have shown a consistent relationship between serum
inﬂiximab concentrations and clinical outcomes including
clinical response, clinical remission, and mucosal healing.
These outcomes were signiﬁcantly more likely to occur in
patients with higher inﬂiximab concentrations than in those
with lower drug concentrations. These ﬁndings in UC are
consistent with previous reports of an association between
serum levels of inﬂiximab and efﬁcacy in patients with IBD,
rheumatoid arthritis, and psoriasis.5–8,18–20 A positive
exposure-response relationship also was observed for goli-
mumab (another anti-TNF biologic) in patients with UC.21
Furthermore, our data originated from large-scale trials
that prospectively evaluated a large number of well-
characterized patients. In particular, these analysesincluded data for the approved 5-mg/kg dose as well as the
highest studied dose in UC (ie, 10 mg/kg) and thus covered
a wide range of serum inﬂiximab concentrations. As a result,
these analyses provide more precise estimates of threshold
concentrations associated with efﬁcacy and avoid con-
founding factors that were present in previous evaluations.
Although the consistency and statistical validity of the
observed association indicates that a positive correlation
exists between inﬂiximab concentrations and efﬁcacy, it is
important to contextualize our ﬁndings. For induction, the
presence of an inﬂiximab concentration of approximately 41
mg/mL at week 8 was associated with a PPV of 80% and a
negative predictive value (NPV) of 42% for the outcome of
clinical response at week 8. Based on the speciﬁcity and
sensitivity values derived from the ROC analysis of inﬂix-
imab induction data, patients with serum inﬂiximab con-
centrations greater than 41 mg/mL have almost twice the
likelihood of achieving clinical response at week 8
compared with those who do not achieve this target (posi-
tive likelihood ratio, 1.7). For more effective patient man-
agement; however, it would be preferable to predict the
clinical outcome at week 8 based on earlier measurements.
Accordingly, although our results showed that the pre-
infusion concentration at week 2 did not predict clinical
response at week 8, the preinfusion concentration at week 6
may be a predictor of subsequent response. A likely
Figure 4. ROC curves for the relationship between serum inﬂiximab concentrations and clinical response in ACT-1 and ACT-2
at (A) induction week 8, (B) maintenance week 30, and (C) maintenance week 54 (ACT-1 only) among patients treated with
inﬂiximab 5 or 10 mg/kg. (A) CPW2, CPW6, CW8, (B and C) CPW14, CPW30, or (C) CPW54 (ACT-1 only) represent the ROC
curves for clinical response and serum inﬂiximab concentrations at weeks 2, 6, 8, 14, 30, and 54, respectively, all preinfusion
except week 8. A, area under the ROC curve.
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concentration at week 6 is more reﬂective of drug clearance
than the inﬂiximab concentration at week 2, which reﬂects
the initial phase of drug loading.
With respect to maintenance inﬂiximab therapy, the
largest amount of data (ACT-1 and ACT-2 combined) was
available at week 30, and the threshold at this time pointwas deﬁned by ROC analysis at 3.7 mg/mL, with a PPV of
82% and an NPV of 51% for the maintenance of clinical
response at week 30. These results show that patients with
a serum inﬂiximab concentration greater than 3.7 mg/mL at
steady-state are more than twice as likely to be in clinical
response during maintenance compared with patients who
do not achieve this target (positive likelihood ratio, 2.3).
Table 3.Target Serum Inﬂiximab Concentration Thresholds for Clinical Response Based on the ROC Curve Analyses Among
Patients Treated With Inﬂiximab 5 or 10 mg/kg in ACT-1 and ACT-2
Efﬁcacy end point Inﬂiximab pharmacokinetic metric ROC analysis metric Estimate
Clinical response during induction
at week 8
Concentration at week 8 Threshold, mg/mL 41.2
Sensitivity 63%
Speciﬁcity 62%
NPV 42%
PPV 80%
Concentration at week 6 Threshold, mg/mL 22.0
Sensitivity 60%
Speciﬁcity 62%
NPV 41%
PPV 78%
Clinical response during maintenance
at week 30
Concentration at week 14 Threshold, mg/mL 5.1
Sensitivity 66%
Speciﬁcity 63%
NPV 54%
PPV 74%
Concentration at week 30 Threshold, mg/mL 3.7
Sensitivity 65%
Speciﬁcity 71%
NPV 51%
PPV 82%
Clinical response during maintenance
at week 54 (ACT-1 only)
Concentration at week 14 Threshold, mg/mL 3.5
Sensitivity 82%
Speciﬁcity 50%
NPV 72%
PPV 63%
Concentration at week 30 Threshold, mg/mL 2.4
Sensitivity 86%
Speciﬁcity 62%
NPV 77%
PPV 76%
Concentration at week 54 Threshold, mg/mL 1.7
Sensitivity 89%
Speciﬁcity 64%
NPV 74%
PPV 83%
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at week 30 is most representative of steady-state trough
concentration for both ACT studies, more weight should be
given to the threshold estimate from the ROC analyses at
this time point compared with the week-54 maintenance
time point in ACT-1. Nonetheless, our analysis showed that
preinfusion serum inﬂiximab concentrations at week 14
also may be predictive of clinical response during mainte-
nance. Speciﬁcally, a serum inﬂiximab concentration of 5.1
mg/mL or higher at week 14 also was associated with
clinical response at week 30. The serum inﬂiximab con-
centration threshold of 5.1 mg/mL at week 14 is consistent
with that deﬁned by ROC analysis for week 30 (3.7 mg/mL)
when consideration is given to the fact that the concentra-
tion at week 14 theoretically is expected to be slightly
higher than the concentration at week 30 because only 8
weeks (1 maintenance dose interval) have elapsed before
the week-14 sampling, after the 3 induction doses at weeks
0, 2, and 6. Furthermore, the threshold serum inﬂiximab
concentration of 3.7 mg/mL is consistent with that estimated
for patients with Crohn’s disease in a Crohn’s diseaseclinical trial evaluating inﬂiximab in a new long term
treatment regimen (ACCENT 1), in which a serum inﬂiximab
level of 3.5 mg/mL at week 14 was associated with sustained
durable response through week 54.22
In these analyses, patients in the lowest inﬂiximab con-
centration quartile were found to have a higher incidence of
ATI and lower serum albumin concentrations. The effects of
albumin on serum inﬂiximab concentrations and efﬁcacy in
UC were reported previously.23 Although the occurrence of
antibodies to TNF inhibitors has been cited as a possible
cause for loss of therapeutic effect,10,13,24 the multivariable
logistic regression analysis showed that ATI status was not
associated strongly with successful induction of clinical
response at week 8 or maintenance of response at week 30.
Overall, the data from the multivariable model suggest that
low serum inﬂiximab concentrations (which could result
from the presence of ATI) are associated more directly with
a decreased response rather than just the occurrence of ATI.
This ﬁnding is consistent with conclusions from a system-
atic review of the impact of ATI in Crohn’s disease,25 as well
as previously published ﬁndings of the ACT trial, which
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higher in patients who had inconclusive ATI status (with
higher serum inﬂiximab concentrations) compared with
those who tested positive or negative for ATI (with lower
serum inﬂiximab concentrations).2 Furthermore, other in-
vestigators have reported that some ATI may be transient
and do not lead to worse clinical outcomes unless these ATI
levels are sustained.26 The persistence of ATI was not
assessed in the current analysis to make this determination.
Notwithstanding this apparent lack of effect of ATI status
on efﬁcacy, it should be noted that the assay used for these
ATI assessments was only able to detect ATI accurately in
the absence of detectable circulating inﬂiximab. Also, there
likely is some bias from missing data because patients who
withdrew early from the study because of lack of efﬁcacy
may not have had a comprehensive assessment of ATIs. It is
possible that a higher proportion of these patients may have
developed ATIs compared with those who continued in the
trial.
Another important ﬁnding in the current study was that
although patients with the poorest outcomes generally
showed relatively lower serum inﬂiximab concentrations,
they did so at both dose levels in the ACT studies. Although
the reason for this phenomenon is unknown, this counter-
intuitive ﬁnding suggests an intricate relationship between
inﬂiximab pharmacodynamics and its systemic clearance,
such that patients who are more likely to respond better to
inﬂiximab have intrinsically lower clearance of the drug.
Because the overall inﬂiximab clearance is unchanged within
the dose range evaluated in the ACT trials,4 this hypothesis
could explain why, despite higher inﬂiximab dose and higher
inﬂiximab concentrations, the proportion of patients
achieving efﬁcacy outcomes remained largely unchanged
when the respective dose-stratiﬁed concentration quartiles
were compared, most strikingly in the lowest inﬂiximab
concentration quartiles (Supplementary Figure 4). One
possible inference from these data is the existence of a group
of patients who may not be treated effectively with inﬂix-
imab owing to high clearance rates, regardless of the dose. It
should be acknowledged, however, that the earlier-described
hypothesis is not supported by the results of several studies
that have shown the beneﬁts of increasing the inﬂiximab
dose in some patients with IBD or rheumatoid arthritis who
lose response.27,28 Nonetheless, these ﬁndings suggest that
clinicians should carefully weigh the need for a dose
adjustment when applicable, considering that not all patients
may beneﬁt from such a dose increase.
The current results had some limitations. First, although
the relationship between serum inﬂiximab concentrations
and efﬁcacy outcomes appears to be both consistent and
robust, these results are retrospective and may have been
confounded by other determinants of both drug concentra-
tions and outcomes. These data, however, were generated
from large randomized trials in which known confounders
were identiﬁed prospectively and in which randomization
would be expected to result in an even distribution of con-
founding variables between the experimental groups.
Nevertheless, prospective studies designed to assess the
value of inﬂiximab concentration–guided dose escalation interms of efﬁcacy and potential impact on safety could provide
valuable information pertaining to a more optimized
approach toward inﬂiximab therapy of UC. One such study
suggests that therapeutic drug monitoring may predict the
likelihood of achieving mucosal healing after inﬂiximab dose
escalation in IBD.29 The positive ﬁndings of a small ran-
domized trial of therapeutic drug monitoring in patients with
Crohn’s disease who experienced a loss of response to
inﬂiximab also are encouraging.30 It also generally is held
that a therapeutic drugmonitoring approach using treatment
algorithms in the management of secondary loss of response
may be more rational than empiric dose escalation.31
The results of these analyses also may be limited by
the fact that the serum inﬂiximab concentrations were
measured using a proprietary assay not presently available
commercially. As a result, research is needed to cross-validate
the assay with those available to physicians to help translate
these identiﬁed inﬂiximab concentrations into practice set-
tings. In addition, the low NPV and low positive likelihood
ratio associatedwith the identiﬁed threshold imply that false-
negative results may be common and additional clinical
judgment will be needed to manage patients who show con-
centrations less than the target threshold. Conversely, the
magnitude of the PPV at the identiﬁed thresholds may reas-
sure a clinician that a given patient is not undertreated if
serum drug concentrations are greater than these thresholds.
In summary, we have established that there is a strong
association between serum inﬂiximab concentration and
efﬁcacy outcomes in patients with UC. The predictive value
of serum inﬂiximab concentrations on subsequent efﬁcacy
outcomes in these patients also was shown. These results
further highlight the possibility of inﬂiximab dose optimi-
zation, particularly in patients who are likely to fail to
maintain efﬁcacy beneﬁt while receiving the standard dose
regimen. The target serum inﬂiximab threshold concentra-
tions and corresponding time points for inﬂiximab mea-
surement suggested by the analyses could assist the
clinician in understanding the mechanism whereby an in-
dividual patient is not achieving the expected efﬁcacy.
Whether these results can be exploited to achieve better
outcomes for patients with UC will need to be assessed in a
prospective study designed to conﬁrm the growing evidence
that concentrations of inﬂiximab may need to be optimized
to maintain efﬁcacy and thus can provide guidance to
clinicians in the management of patients with UC.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2014.08.035.References
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Supplementary Figure 1. Inﬂiximab dosing and pharmacokinetic sampling scheme for ACT-1 and ACT-2. Open circles and
squares indicate treatment with inﬂiximab 5 mg/kg or 10 mg/kg, respectively.
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Supplementary Figure 2. Distribution of inﬂiximab concentrations among patients treated with inﬂiximab 5 or 10 mg/kg in
ACT-1 and ACT-2. CPW2, CPW6, CW8, CPW14, CPW30, and CPW54 (ACT 1 only) represent serum inﬂiximab concentrations
at weeks 2, 6, 8, 14, 30, and 54, respectively; all preinfusion with the exception of week 8. Box plots below show median (solid
line in box), interquartile range (upper and lower boundaries of box), mean (dotted line), and distribution of individual patient
concentrations (circles).
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Supplementary Figure 4. Proportion of patients achieving
clinical response by serum inﬂiximab concentration quartiles in
ACT-1 and ACT-2 stratiﬁed by dose regimen at induction week
8 (A) and maintenance week 30 (B). The trend of the proportion
of patientsachievingclinical outcomesacross thequartileswas
evaluated using the 1-sided Cochrane-Armitage trend test.
=
Supplementary Figure 3. Proportion of patients achieving
efﬁcacy outcomes by serum inﬂiximab concentration quartiles
in ACT-1 and ACT-2 for the 5-mg/kg treatment group at in-
ductionweek 8 (A),maintenanceweek 30 (B), andmaintenance
week 54 (C; ACT-1 only). The trend of the proportion of patients
achieving clinical outcomes across the quartileswas evaluated
using the 1-sided Cochrane-Armitage trend test.
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Supplementary Figure 6. The inﬂuence of serum inﬂiximab concentration on subsequent efﬁcacy outcome by inﬂiximab dose.
Median serum inﬂiximab concentrations at week 30 are shown for patients who did and did not achieve clinical remission at
week 54 (ACT-1 only) for patients receiving inﬂiximab 5 mg/kg (A) and 10 mg/kg (B) and proportions of patients in clinical
remission at week 54 (ACT-1 only) by serum inﬂiximab concentration quartiles at week 30 among patients in remission at week
30 for patients receiving inﬂiximab 5 mg/kg (C) and 10 mg/kg (D).
=
Supplementary Figure 5. The inﬂuence of serum inﬂiximab concentration on subsequent efﬁcacy outcome for the combined
5- and 10-mg/kg inﬂiximab doses. Median serum inﬂiximab concentrations at weeks 30, 14, and 8 are shown for patients who
did and did not achieve clinical remission at weeks 54 (ACT-1 only), 30, and 30, respectively (A -C) and proportions of patients
in clinical remission at weeks 54 (ACT-1 only), 30, and 30 by serum inﬂiximab concentration quartiles at weeks 30, 14, and 8,
respectively, among patients in remission at weeks 30, 8, and 8, respectively (D-F). For all panels, the 5- and 10-mg/kg doses
of inﬂiximab are combined.
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